Today: 21 May 2026
Trip.com’s antitrust shock hits Hong Kong stocks as Hang Seng slips; Alibaba’s Qwen upgrade draws focus
15 January 2026
2 mins read

Trip.com’s antitrust shock hits Hong Kong stocks as Hang Seng slips; Alibaba’s Qwen upgrade draws focus

HONG KONG, Jan 15, 2026, 16:30 HKT

  • Hang Seng slipped as Trip.com dropped following a China antitrust probe
  • Alibaba introduced new features in its Qwen app designed to streamline everyday activities such as ordering food and booking travel
  • Investors are eyeing China’s latest data alongside new moves to rein in leverage in mainland markets

Hong Kong shares slipped Thursday, the Hang Seng Index ending 0.5% lower at 26,866.29. The index fluctuated between 26,808.35 and 27,206.84 during the session. Trip.com led the decline, tumbling as much as 21.7% on news of an antitrust probe before trimming its losses, dragging down sentiment across the tech sector.

The pullback follows a robust start to the week that saw the benchmark climb past 27,000, fueled by global investors shifting focus away from U.S. markets and the yuan hitting its strongest level against the dollar since May 2023. “The Hong Kong market has been largely driven by moves in mainland A shares,” said Kenny Ng Lai-yin, a strategist at Everbright Securities International, referring to stocks listed in Shanghai and Shenzhen. South China Morning Post

Macro factors have been key drivers lately. China posted a record trade surplus close to $1.2 trillion in 2025, thanks largely to exports outside the U.S., according to a Reuters poll summary. Larry Hu, Macquarie’s chief China economist, cautioned that a drop in exports might push Beijing toward a bigger domestic stimulus effort.

China’s State Administration for Market Regulation launched an investigation into Trip.com on Wednesday, suspecting the online travel giant of abusing its dominant market position. Trip.com responded, saying it is “actively” cooperating and will “fully implement regulatory requirements.” According to Reuters, if violations are confirmed, fines can range from 1% to 10% of the company’s previous year sales. Reuters

Alibaba, a key mover in Hong Kong this week, aimed to seize back the spotlight Thursday with a boost to its Qwen AI app. The update adds features letting users order food delivery and book travel directly through the chat interface. “What we are launching today represents a shift from models that understand to systems that act,” said Wu Jia, a vice president at Alibaba Group, as the company intensified its consumer AI push to compete with local giants like ByteDance and Tencent. MarketScreener

Hong Kong’s market closed higher Wednesday following stronger-than-expected December trade data from China, according to AASTOCKS. Exports rose 6.6% year-on-year, while imports increased 5.7%. The Hang Seng gained 151 points to 26,999. Alibaba surged 5.7%, but Trip.com dropped 6.5% after news of an investigation, the report added.

China’s major stock exchanges have increased the minimum margin requirement for margin trading from 80% to 100% on new contracts. The Shanghai Stock Exchange noted that margin trading had grown “notably more active” and liquidity was “relatively ample.” China Daily

Deal and stock-specific news continued to move markets on Thursday. S.F. Holding jumped after agreeing to acquire an 8.5% stake in J&T Global for HK$8.3 billion. Investors also kept an eye on China’s credit lending figures, ahead of next week’s key data releases, including GDP and the loan prime rate, according to a TradingView summary of Trading Economics data.

But sentiment can shift quickly. A fresh wave of selling in global tech stocks, combined with rising geopolitical tensions, is putting pressure on Hong Kong’s rally. Kyle Rodda, an analyst at Capital.com, pointed to a “rotation” dragging down major indexes, even as capital flows into other market segments. Reuters

Hong Kong is currently weighing two opposing forces: China’s strong export numbers and policy backing, versus the headwinds from regulatory crackdowns and tighter leverage rules. The upcoming China data release will tip the balance one way or the other.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
BP stock slides in London as $5 billion write-down warning puts buyback in focus
Previous Story

BP stock slides in London as $5 billion write-down warning puts buyback in focus

Broadcom stock falls again as China targets VMware; RBC says OpenAI upside ‘less clear’
Next Story

Broadcom stock falls again as China targets VMware; RBC says OpenAI upside ‘less clear’

Go toTop